ArticleDiabetology & metabolic syndrome2026
A randomized controlled trial of drug-coated balloon versus conventional balloon angioplasty in diabetic patients with lower extremity arteriosclerosis obliterans: outcomes in ankle-brachial index and restenosis rate.
Article in Diabetology & metabolic syndrome, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetic lower extremity arteriosclerosis obliterans (DLASO) is a severe complication with high risks of limb loss and mortality. While drug-coated balloons (DCBs) are effective in peripheral artery disease, robust evidence for their use in specifically diabetic populations is limited.
objectiveTo evaluate the efficacy and safety of paclitaxel-coated balloon angioplasty versus conventional plain balloon angioplasty (POBA) for the treatment of DLASO in a randomized controlled trial.
methodsIn this prospective, single-blind, randomized controlled trial, 60 patients with DLASO were equally assigned to the DCB group or the POBA (control) group. The primary endpoints were primary patency rate and change in ankle-brachial index (ABI) at 12 months. Secondary endpoints included Rutherford classification, target lesion revascularization (TLR), and complications. Follow-up assessments occurred at 1, 3, 6, and 12 months.
resultsThe primary patency rate at 12 months was significantly higher in the DCB group (83.3% [95% CI, 71.8% to 96.7%]) than in the control group (56.7% [95% CI, 41.2% to 78.0%]) (hazard ratio 0.32; log-rank P = 0.023). The mean increase in ABI from baseline to 12 months was also greater in the DCB group (0.31 ± 0.12 vs. 0.21 ± 0.11; mean difference 0.10 [95% CI, 0.04 to 0.16]; P < 0.001). Clinical improvement (Rutherford classification) was more pronounced, and the 12-month TLR rate was lower (0% vs. 3.33%) in the DCB group. Complication rates were comparable between groups (10.00% vs. 13.33%, P > 0.05).
conclusionFor patients with DLASO, paclitaxel-coated balloon angioplasty is superior to conventional balloon angioplasty in maintaining vessel patency, improving perfusion, and promoting clinical outcomes at 12 months, with a similar safety profile.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.